CFRX CONTRAFECT CORP

Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors (CFRX)

LOS ANGELES--(BUSINESS WIRE)--

Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of ContraFect Corporation (NASDAQ: CFRX) investors concerning the Company and its directors’ and officers’ possible violations of state laws.

If you purchased ContraFect stock, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9244, or Bryan Faubus, of GPM, 230 Park Avenue, Suite 530, New York, NY 10169 at 212-682-5340 or at [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
27/03/2018

Underlying

CFRXCONTRAFECT CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTRAFECT CORP

 PRESS RELEASE
Free
CFRX CONTRAFECT CORP

ContraFect Announces FDA Clearance of CF-370 IND Application to Procee...

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study CF-370 is the first engineered lysin therapeutic targeting Gram-negative pathogens allowed to enter a human trial YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that the U.S. Food and Drug Administration (FDA) has notified the company that it has completed the safety review of its Investigational New Drug (I...

October 16, 2023 1 EN
 PRESS RELEASE
Free
CFRX CONTRAFECT CORP

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Devel...

ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development YONKERS, New York, Sept. 19, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston, MA from September 19-22, 2023. Dr. A...

September 19, 2023 1 EN
 PRESS RELEASE
Free
CFRX CONTRAFECT CORP

ContraFect Announces Submission of IND Application to the FDA for its ...

ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370 YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023. The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital...

September 18, 2023 1 EN
 PRESS RELEASE
Free
CFRX CONTRAFECT CORP

ContraFect to Present at the World Anti-Microbial Resistance Congress ...

ContraFect to Present at the World Anti-Microbial Resistance Congress 2023 YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from Septe...

August 28, 2023 1 EN
 PRESS RELEASE
Free
CFRX CONTRAFECT CORP

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of ...

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of t...

June 27, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch